Connect with us

Hi, what are you looking for?



Trump’s Ignorance of Science & Flippant Suggestions are Endangering People’s Lives

The Trump administration’s claim that two anti-malarial drugs, hydroxychloroquine and chloroquine, should be regarded as treatment options for COVID-19 may be one of its most dangerous forms of misinformation yet.

Originally published on blog of Union of Concerned Scientists.

The Trump administration’s claim that two anti-malarial drugs, hydroxychloroquine and chloroquine, should be regarded as treatment options for COVID-19 may be one of its most dangerous forms of misinformation yet. For weeks, the Trump administration has claimed that these drugs can act like a panacea for the disease and, while the administration has recently gone quiet on this messaging, the damage has already been done.

Trump administration dismisses leading vaccine expert

Dr. Rick Bright, a vaccine expert, has recently alleged that his refusal to conform to the Trump administration’s misinformation about two drugs for COVID-19 treatment, hydroxychloroquine and chloroquine, led to his dismissal from his post at the Department of Health and Human Services. First reported on April 21 by STAT News, Dr. Rick Bright was abruptly dismissed from his job as the director of the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), where he was responsible for vaccine development, and was then reassigned to a lower position at the National Institutes of Health (NIH).

Dr. Bright told the New York Times that the reasons for his dismissal appear to be due to his efforts to resist the “broad use of chloroquine and hydroxychloroquine, promoted by the administration as a panacea, but which clearly lack scientific merit.” Dr. Bright added that he “rightly resisted efforts to provide an unproven drug on demand to the American public,” which “have potentially serious risks associated with them, including increased mortality … in COVID-19 patients,” and that “rushing blindly towards unproven drugs can be disastrous and result in countless more deaths.”

Dr. Bright’s words get to the heart of why the Trump administration’s promotion of hydroxychloroquine and chloroquine as some sort of a cure-all to the pandemic is so troubling and potentially dangerous. Science is like a conversation, a series of topics tackled and expanded upon by top experts in the field which, together, can paint a picture of the probable reality of how the world works.

The Trump administration, on the other hand, is threatening to derail the scientific conversation on what drugs can be effective against COVID-19 in a way that is already leading to fear, illness, and even deaths.

The science does not justify the promotion of hydroxychloroquine as a COVID-19 treatment

It is very dangerous to say that a drug can treat COVID-19 without a series of well-established, robust clinical trials. Already, we’ve seen this misinformation by the administration leading to hydroxychloroquine poisonings and deaths in Nigeria and the US; a mass public scramble for the drugs such that lupus and rheumatoid arthritis patients, who depend on hydroxychloroquine for pain management, are unable to obtain it; and some pharmaceutical companies have hiked the price up by 350 percent for a component used to make the hydroxychloroquine drug.

While the anti-malarial drugs hydroxychloroquine and chloroquine have been approved for human use since the 1950s and 1930s, respectively, it very well established that these drugs can prove deadly to a subset of people with heart problems like arrhythmias. In fact, a Brazilian study looking at chloroquine as a possible treatment for COVID-19 had to be stopped midway because multiple participants developed irregular heart rates, of which 11 patients died. And considering that people with underlying heart conditions often face some of the worst symptoms of COVID-19, the ability of hydroxychloroquine and chloroquine to act as an effective treatment during the pandemic may be further in question.

The science behind whether these drugs can treat COVID-19 is mixed. Some early laboratory studies and small-scale human studies in China and France have showed some promise, but several of the human trials have faced intense criticism for poor methodology or a lack of peer review.

A recent nationwide study of 368 patients in US veterans hospitals, released in a preprint form prior to peer review, looked at the effectiveness of hydroxychloroquine, with or without the antibiotic azithromycin, for treating COVID-19. The researchers found that hydroxychloroquine made no difference in quelling the symptoms severe enough to require a ventilator, and that patients who only took hydroxychloroquine had a higher risk of death than those who did not take the drug.

The National Institute of Allergy and Infectious Diseases (NIAID), the agency headed by Dr. Anthony Fauci, recently conveyed a panel of experts that weighed the evidence and recommended against using a combination of hydroxychloroquine and azithromycin for the treatment of COVID-19 patients because of potential toxicities. The expert panel concluded that there was “insufficient clinical data to recommend either for or against” the use of hydroxychloroquine or chloroquine alone for the treatment of COVID-19.

At the same time, several high-profile research institutions and pharmaceutical companies consider the preliminary evidence for hydroxychloroquine and chloroquine promising enough to launch large-scale robust clinical trials which will likely put us on firmer ground as to the drugs’ effectiveness against COVID-19.

Some of the most promising clinical studies include the National Institutes of Health’s (NIH) blinded, placebo-controlled randomized clinical trial of 500 patients for hydroxychloroquine; Novartis’ 450-person trial for hydroxychloroquine using the “gold standard” of a randomized, double-blind placebo-controlled study; and the World Health Organization’s SOLIDARITY trial of four treatment options, including chloroquine and hydroxychloroquine in combination, for thousands of patients in dozens of countries.

Robust clinical trials matter

It is still an open question as to whether hydroxychloroquine and chloroquine has some potential benefits for treating COVID-19. For instance, it is possible that the drugs may be promising in certain drug combinations but not others; the drugs may prove to be beneficial for some patients at certain stages of a disease but not others; or the drugs could provide benefits for people with certain demographic or underlying health conditions but not others.

There are simply too many unknowns to tell. This is why we conduct clinical trials with robust methodology. The history of science and medicine are littered with examples of people excited about certain treatment options that later proved to be detrimental under randomized clinical trials. There is a bitter lesson here: touting miracle cures without proper scientific evidence can led to heartbreaking situations for patients.

The Trump administration — an administration with a three-year history of censoring scientists, disbanding scientific advisory committees, and burying scientific studies — and its attempts to promote unproven drug treatments for COVID-19, against the advice of its own scientists, is more than just irresponsible. It is misinformation that will likely compromise the health of thousands of people in the middle of the most deadly pandemic experienced in our lifetimes.

Sign up for daily news updates from CleanTechnica on email. Or follow us on Google News!

Have a tip for CleanTechnica, want to advertise, or want to suggest a guest for our CleanTech Talk podcast? Contact us here.

Electrifying Industrial Heat for Steel, Cement, & More

I don't like paywalls. You don't like paywalls. Who likes paywalls? Here at CleanTechnica, we implemented a limited paywall for a while, but it always felt wrong — and it was always tough to decide what we should put behind there. In theory, your most exclusive and best content goes behind a paywall. But then fewer people read it! We just don't like paywalls, and so we've decided to ditch ours. Unfortunately, the media business is still a tough, cut-throat business with tiny margins. It's a never-ending Olympic challenge to stay above water or even perhaps — gasp — grow. So ...
If you like what we do and want to support us, please chip in a bit monthly via PayPal or Patreon to help our team do what we do! Thank you!
Written By

We publish a number of guest posts from experts in a large variety of fields. This is our contributor account for those special people, organizations, agencies, and companies.


You May Also Like


This is a heartwarming video of a contract tracer who won a Tesla last week. His reaction was filmed by his coworkers and reported...

Air Quality

New method allows researchers to measure levels of NO2 on a finer scale, revealing disparities in exposure during COVID Originally published on Washington University...


Dealing with our climate crisis continues to be top of mind, although batteries, magnets, and exotic elements also captured the imagination Story by Julie Chao...


The 2021–2022 WRI Ross Center Prize for Cities launched on World Cities Day, October 31, 2021. Submissions are open until February 15, 2022. Find...

Copyright © 2023 CleanTechnica. The content produced by this site is for entertainment purposes only. Opinions and comments published on this site may not be sanctioned by and do not necessarily represent the views of CleanTechnica, its owners, sponsors, affiliates, or subsidiaries.